Bohen Sean 4
4 · Olema Pharmaceuticals, Inc. · Filed Oct 15, 2021
Insider Transaction Report
Form 4
Bohen Sean
DirectorPRESIDENT AND CEO
Transactions
- Exercise/Conversion
Common Stock
2021-10-14$4.82/sh+5,000$24,120→ 57,514 total - Sale
Common Stock
2021-10-14$30.42/sh−4,649$141,423→ 52,865 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-10-14−5,000→ 966,316 totalExercise: $4.82Exp: 2030-11-18→ Common Stock (5,000 underlying) - Sale
Common Stock
2021-10-14$31.17/sh−351$10,941→ 52,514 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- [F2]The weighted average sale price for the transaction reported was $30.42, and the range of prices were between $30.00 and $30.99. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $31.17, and the range of prices were between $31.00 and $31.28. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4](A) 256,992 of the shares subject to the option vest on September 1, 2021, (B) 2,411 of the shares subject to the option vest on January 1, 2022 and 2,410 of the shares subject to the option vest on January 1 of each of 2023 and 2024 and (C) 23,143 of the shares subject to the option vest on the 1st day of each month (other than on September 1, 2021 and each of January 1, 2022, 2023 and 2024) following September 1, 2021, plus an additional 23 shares on September 1, 2024. Subject to, in each case of (A) - (C) above, the Reporting Person's continuous service on each applicable vesting date. The stock option is early exercisable.